Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC
Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.
EP: 1.Overview of PD-L1 Testing in Advanced NSCLC
EP: 2.Subgrouping Patients with Advanced NSCLC for Tailored Treatment
EP: 3.CTLA-4 Targeted Regimens in Advanced NSCLC
EP: 4.Updates in Gender-Based Treatment for Patients with Advanced NSCLC
EP: 5.Data Updates on Single-Agent Immunotherapy in Advanced NSCLC
EP: 6.Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC
Now Viewing
EP: 7.Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC
EP: 8.Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial
EP: 9.Combination Chemotherapy and Immunotherapy for Advanced NSCLC
EP: 10.The Evolution of Chemoimmunotherapy in Advanced NSCLC
Sponsored in part by Regeneron. Content independently created by OncLive.
Related Videos
Related Content
